Baxalta Company Profile (NYSE:BXLT)

About Baxalta (NYSE:BXLT)

Baxalta logoBaxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta's categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:BXLT
  • CUSIP: N/A
  • Web: www.baxalta.com/
Average Prices:
  • 50 Day Moving Avg: $46.02
  • 200 Day Moving Avg: $46.02
  • 52 Week Range: $37.44 - $46.52
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 18.12
  • P/E Growth: 0.00
Profitability:
  • Net Margins: 9.37%
  • Return on Equity: 14.28%
  • Return on Assets: 4.62%
 

Frequently Asked Questions for Baxalta (NYSE:BXLT)

What is Baxalta's stock symbol?

Baxalta trades on the New York Stock Exchange (NYSE) under the ticker symbol "BXLT."

How were Baxalta's earnings last quarter?

Baxalta Inc (NYSE:BXLT) issued its quarterly earnings data on Thursday, April, 28th. The company reported $0.47 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.46 by $0.01. The company had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.47 billion. Baxalta had a net margin of 9.37% and a return on equity of 14.28%. The company's revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.40 earnings per share. View Baxalta's Earnings History.

Who are some of Baxalta's key competitors?

How do I buy Baxalta stock?

Shares of Baxalta can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Baxalta's stock price today?

One share of Baxalta stock can currently be purchased for approximately $46.02.


MarketBeat Community Rating for Baxalta (NYSE BXLT)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  105
MarketBeat's community ratings are surveys of what our community members think about Baxalta and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Baxalta (NYSE:BXLT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Baxalta (NYSE:BXLT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/6/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
12/9/2015Barclays PLCBoost Price TargetEqual Weight$38.00 -> $40.00N/AView Rating Details
10/27/2015William BlairReiterated RatingBuyN/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Baxalta (NYSE:BXLT)
Earnings by Quarter for Baxalta (NYSE:BXLT)
Earnings History by Quarter for Baxalta (NYSE BXLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/28/2016Q116$0.46$0.47$1.47 billion$1.50 billionViewN/AView Earnings Details
2/16/2016Q415$0.56$0.57$1.71 billion$1.80 billionViewN/AView Earnings Details
10/29/2015Q315$0.49$0.56$1.51 billion$1.60 billionViewListenView Earnings Details
7/30/2015Q215$0.50$0.40$1.41 billion$1.47 billionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Baxalta (NYSE:BXLT)
Current Year EPS Consensus Estimate: $2.19 EPS
Next Year EPS Consensus Estimate: $2.54 EPS

Dividends

Current Dividend Information for Baxalta (NYSE:BXLT)
Most Recent Dividend:7/1/2016
Dividend Yield:0.00%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:0.00% (Based on This Year's Estimates)
0.00% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Baxalta (NYSE:BXLT)

Dividend History by Quarter for Baxalta (NYSE BXLT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/10/2016Quarterly$0.076/8/20166/10/20167/1/2016
5/10/2016quarterly$0.070.66%6/8/20166/10/20167/1/2016
2/24/2016quarterly$0.070.72%3/8/20163/10/20164/1/2016
11/18/2015quarterly$0.070.81%12/2/201512/4/20151/4/2016
7/28/2015quarterly$0.079/2/20159/4/201510/1/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Baxalta (NYSE:BXLT)
Insider Trades by Quarter for Baxalta (NYSE:BXLT)
Institutional Ownership by Quarter for Baxalta (NYSE:BXLT)
Insider Trades by Quarter for Baxalta (NYSE:BXLT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/24/2016Albert P L StrouckenDirectorSell5,660$39.98$226,286.80View SEC Filing  
2/25/2016Blake E DevittDirectorBuy5,900$39.17$231,103.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Baxalta (NYSE:BXLT)
Latest Headlines for Baxalta (NYSE:BXLT)
Source:
DateHeadline
finance.yahoo.com logoDurham company bulks up executive suite as cancer therapy development moves forward
finance.yahoo.com - July 13 at 5:53 PM
finance.yahoo.com logoAlexion: Look Out Below!
finance.yahoo.com - May 23 at 1:00 PM
nasdaq.com logoJulian Robertson Buys Adobe and Sells Apple in 1st Quarter - Nasdaq
www.nasdaq.com - May 16 at 4:10 PM
americanbankingnews.com logoBaxalta (BXLT) Receiving Somewhat Positive Press Coverage, Report Finds
www.americanbankingnews.com - May 4 at 1:01 AM
americanbankingnews.com logoBaxalta (BXLT) Receives Daily Media Impact Rating of 0.56
www.americanbankingnews.com - April 30 at 10:18 AM
thestreet.com logoTakeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation
www.thestreet.com - January 9 at 5:14 PM
bizjournals.com logoCTI Biopharma stock revived after FDA ruling, reverse stock split
www.bizjournals.com - January 6 at 9:27 PM
uk.finance.yahoo.com logoShire reiterates full-year guidance after in-line Q3
uk.finance.yahoo.com - November 1 at 4:02 PM
bizjournals.com logoHouston cancer company closes additional funding - Houston Business Journal
www.bizjournals.com - October 10 at 3:54 PM
moodys.com logoShire plc -- Moody's assigns Baa3 to Shire's sr. notes; stable outlook
www.moodys.com - September 16 at 3:56 PM
seekingalpha.com logoTracking Stephen Mandel's Lone Pine Capital Portfolio - Q2 2016 Update - Seeking Alpha
seekingalpha.com - August 25 at 4:05 PM
streetinsider.com logoForm N-PX WELLS FARGO FUNDS TRUST For: Jun 30 - StreetInsider.com
www.streetinsider.com - August 25 at 8:54 AM
seekingalpha.com logoTracking Tweedy Browne Portfolio - Q2 2016 Update - Seeking Alpha
seekingalpha.com - August 12 at 12:40 PM
moodys.com logoBaxter International Inc. -- Moody's rates Baxter's new notes Baa2; outlook stable
www.moodys.com - August 10 at 3:28 PM
seekingalpha.com logoApple-Twitter: Why Not? - Seeking Alpha
seekingalpha.com - August 7 at 3:59 PM
bloomberg.com logoShire Says Baxalta Combination to Boost Profit and Sales
www.bloomberg.com - August 2 at 8:51 AM
uk.finance.yahoo.com logoShire upgrades Baxalta cost savings after Q2 earnings beat
uk.finance.yahoo.com - August 2 at 8:51 AM
uk.finance.yahoo.com logoShire lifts earnings and Baxalta cost saving targets
uk.finance.yahoo.com - August 2 at 8:51 AM
wsj.com logo[$$] Shire Earnings: What to Watch
www.wsj.com - August 1 at 4:00 PM
investopedia.com logo3 Mutual Funds Focusing on Arbitrage Profits (MERFX, ARBFX)
www.investopedia.com - July 28 at 10:00 AM
cnbc.com logoDan Loeb's Third Point tells why investing is like 'Game of Thrones'
www.cnbc.com - July 26 at 8:26 PM
bloomberg.com logoBaxter Beats Earnings Estimates, Raises Full-Year Guidance
www.bloomberg.com - July 26 at 7:11 AM
nasdaq.com logoTweedy Browne Global Value Fund Makes Trades Around the World - Nasdaq
www.nasdaq.com - July 13 at 3:59 PM
seekingalpha.com logoBiotech ETF IBB Short Squeeze May Be Ahead - Seeking Alpha
seekingalpha.com - July 12 at 4:05 PM
investopedia.com logoTop 3 Stocks Hedge Funds Bought in Q1, 2016
www.investopedia.com - June 21 at 10:00 AM
investopedia.com logoTop 3 Stocks Hedge Funds Bought in Q1, 2016
www.investopedia.com - June 21 at 10:00 AM
investopedia.com logoAre Hedge Funds Trying to Catch the Falling Knife? (AMZN, NFLX)
www.investopedia.com - June 19 at 3:52 PM
finance.yahoo.com logoFitch Downgrades Baxalta to 'BBB'; Withdraws Ratings
finance.yahoo.com - June 7 at 12:17 PM
moodys.com logoShire plc -- Moody's downgrades Baxalta to Baa3; stable outlook
www.moodys.com - June 6 at 1:02 PM

Social

Chart

Baxalta (BXLT) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff